National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

The proposed licensed indication is for use (in combination with trastuzumab and docetaxel) in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. 

Rapid Review

Commenced Completed Outcome
14/01/2013 31/01/2013 Pharmacoeconomic Evaluation Recommended

 Pharmacoeconomic Evaluation

Commenced  Completed Outcome
 02/05/2013  28/08/2013  Reimbursement not recommended

The NCPE believes that pertuzumab in combination with trastuzumab and docetaxel is not a cost-effective treatment for adults with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous anti-HER2 therapy or chemotherapy.

Pertuzumab (Perjeta®) summary